Neuromodulation Research
Engineering the Next Generation of Neuromodulation
General Biotech develops advanced biotechnology compounds designed to influence multiple neurological signaling systems with precision.
Its lead research program, GB-101 Synaptiva, explores a multimodal approach to cholinergic neuromodulation.
GB-101 Synaptiva
Multimodal Cholinergic Neuromodulation
GB-101 is being developed as a multimodal cholinergic neuromodulator, designed around several complementary neurological mechanisms rather than a single molecular target.
Full program detail →
- 01M1
Primary Mechanism
M1 Muscarinic Receptor Activation
Designed to enhance cholinergic signaling pathways associated with cognition and neuronal activity.
- 02AChE
Complementary Mechanism
Controlled AChE Modulation
Intended to prolong the activity of naturally released acetylcholine.
- 03D2 / 5-HT1A
Secondary Predicted Activity
D2 + 5-HT1A Modulation
Computational research suggests additional interactions with dopaminergic and serotonergic signaling systems that require experimental validation.
- 04α-ADR
Research Focus
α-Adrenergic Activity
Potential adrenergic interactions would be treated as an important selectivity and safety consideration during development.
Technology
One Molecule. Multiple Neural Pathways.
General Biotech combines molecular engineering, computational pharmacology, receptor modeling, and neurological research to investigate compounds capable of interacting with interconnected signaling systems.
Cholinergic
Dopaminergic
Serotonergic
Synaptic Biology
Research Platform
Beyond GB-101
Synaptiva would establish General Biotech's broader Neuromodulation Platform, supporting future compounds targeting receptors, enzymes, transporters, and signaling pathways involved in neurological function.
Receptors
Enzymes
Transporters
Signaling Pathways